Organon & Co. (4OGN.TI)

Compare

15.04

+0.68

(+4.74%)

As of November 12 at 9:20:20 AM GMT+1. Market Open.

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

JERSEY CITY, N.J., December 19, 2024--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th

Business Wire 22 days ago

OGN
FDA approves Organon’s VTAMA cream, 1% for the treatment for AD

Organon (OGN) announced that the U.S. Food and Drug Administration or FDA has approved VTAMA or tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis AD in adults and pediatric patients 2 years of age and older.Organon received the FDA approval prior to its extended target action date PDUFA of March 12. “With the FDA’s approval of VTAMA cream in atopic dermatitis for adults and children as young as 2 years old, there

TipRanks 24 days ago

OGN
FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

JERSEY CITY, N.J., December 16, 2024--Organon's VTAMA (tapinarof) cream is a first-in-class therapy with new FDA approval for atopic dermatitis in adults and children aged 2 and older.

Business Wire 25 days ago

OGN
Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem

Despite announcing strong earnings, Organon & Co.'s ( NYSE:OGN ) stock was sluggish. We did some digging and found some...

Simply Wall St. 2 months ago

OGN
Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Organon & Co. ( NYSE:OGN ) shareholders are probably feeling a little disappointed, since its shares fell 3.1% to...

Simply Wall St. 2 months ago

OGN
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

JERSEY CITY, N.J., November 05, 2024--The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Business Wire 2 months ago

OGN
Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Organon & Co.'s ( NYSE:OGN ) investors are due to receive a payment of $0.28 per share on 12th of December. Based on...

Simply Wall St. 2 months ago

OGN
Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Organon ( NYSE:OGN ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.58b (up 4.1% from 3Q 2023). Net...

Simply Wall St. 2 months ago

OGN
Organon Reports Results for the Third Quarter Ended September 30, 2024

JERSEY CITY, N.J., October 31, 2024--Organon Reports Q3 2024 Earnings

Business Wire 2 months ago

OGN
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

SHANGHAI, China & JERSEY CITY, N.J., October 30, 2024--Henlius and Organon announced US FDA has accepted the Biologics License Application (BLA) for HLX14, biosimilar candidate of PROLIA/XGEVA (denosumab).

Business Wire 2 months ago

2696.HK

OGN
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant (NASDAQ: ROIV). Dermavant is a company dedicated to developing and commercializi

GlobeNewswire 2 months ago

ROIV

OGN
Pediatrix Medical Group (MD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Pediatrix Medical Group (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 months ago

OGN

MD
Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Organon (OGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 3 months ago

OGN
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024

JERSEY CITY, N.J., October 09, 2024--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its third quarter 2024 financial results on October 31, 2024, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.

Business Wire 3 months ago

OGN
Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands

Organon Canada, a subsidiary of Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today announced updates to its Canadian leadership team with an appointment and promotion.

CNW Group 3 months ago

OGN
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11

SHANGHAI, China & JERSEY CITY, N.J., September 30, 2024--Henlius and Organon announce primary endpoint met in phase 3 comparative clinical study of Perjeta® (pertuzumab) biosimilar candidate HLX11

Business Wire 3 months ago

OGN
Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada

In recognition of World Contraception Day (WCD) on September 26, Organon Canada, a subsidiary of Organon (NYSE: OGN), a global healthcare company with a focus on women's health, and the Alberta Women's Health Foundation (AWHF), a pan-provincial fundraising brand supporting the advancement of care and research in women's health, are collaborating to show their support for universal access to contraception in Canada.

CNW Group 3 months ago

OGN
Are Options Traders Betting on a Big Move in Organon (OGN) Stock?

Investors need to pay close attention to Organon (OGN) stock based on the movements in the options market lately.

Zacks 3 months ago

OGN
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

JERSEY CITY, N.J., September 18, 2024--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.

Business Wire 3 months ago

OGN
Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?

Style Box ETF report for DES

Zacks 4 months ago

DES

AVUV

OGN

Performance Overview

Return	4OGN.TI	MSCI WORLD
YTD	+4.66%	-0.93%
1-Year	+8.00%	+17.08%
3-Year	-37.96%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Organon & Co. (4OGN.TI)

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

FDA approves Organon’s VTAMA cream, 1% for the treatment for AD

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem

Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Organon Reports Results for the Third Quarter Ended September 30, 2024

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Pediatrix Medical Group (MD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024

Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada

Are Options Traders Betting on a Big Move in Organon (OGN) Stock?

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?

Performance Overview